SAFETY AND EFFICACY OF BEVACIZUMAB PLUS STANDARD FIRST-LINE CHEMOTHERAPY IN PATIENTS WITH METASTATIC COLORECTAL CANCER: FIRST BEAT

被引：0
|
作者：
Van Cutsem, E. [1 ]
Berry, S. [2 ]
Michael, M. [3 ]
Kretzschmar, A. [4 ]
Rivera, F. [5 ]
DiBartolomeo, M. [6 ]
Mazier, M. [7 ]
Andre, N.
Cunningham, D. [8 ]
机构：
[1] Univ Hosp Gasthuisberg, Digest Oncol Unit, B-3000 Louvain, Belgium
[2] Toronto Sunnybrook Reg Canc Ctr, Toronto, ON, Canada
[3] Peter MacCallum Canc Ctr, Dept Haematol & Med Oncol, Melbourne, Vic, Australia
[4] Charite Campus Buch, Berlin, Germany
[5] Hosp M Valdecilla, Santander, Spain
[6] Fdn IRCCS Ist Nazl Tumori, Milan, Italy
[7] PARAXEL Int, Biostat & Programming, Paris, France
[8] Royal Marsden NHS Fdn Trust, Sutton, Surrey, England
来源：
ANNALS OF ONCOLOGY | 2008年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：125 / 125
页数：1
相关论文
共 50 条
  • [41] Bevacizumab in combination with first-line chemotherapy in patients with metastatic colorectal cancer: a meta-analysis
    Hu, W.
    Xu, W. -S.
    Liao, X. -F.
    He, H. -J.
    MINERVA CHIRURGICA, 2015, 70 (06) : 451 - 458
  • [42] Efficacy and safety of sintilimab plus bevacizumab and CAPOX as first-line treatment for patients with RAS-mutant, microsatellite stable, metastatic colorectal cancer
    Wang, Yanrong
    Jia, Ru
    Si, Haiyan
    Ma, Yue
    Fan, Mengjiao
    Zhang, Nan
    Liu, Fangfang
    Shi, Yue
    Jia, Yushan
    Zhang, Yaoyue
    Han, Quanli
    Wang, Zhikuan
    Dai, Guanghai
    BMC CANCER, 2025, 25 (01)
  • [43] Efficacy and Safety of Bevacizumab Combined With First-Line Chemotherapy in Elderly (≥75 Years) Patients With Metastatic Colorectal Cancer: A Real-World Study
    Francois, Eric
    Mineur, Laurent
    Deplanque, Gael
    Laplaige, Philippe
    Smith, Denis
    Gourgou, Sophie
    Tanang, Alexandre
    Ionescu-Goga, Miruna
    Veerabudun, Kalaivani
    Lelarge, Yoann
    Kim, Stefano
    Rollot, Florence
    CLINICAL COLORECTAL CANCER, 2020, 19 (03) : E100 - E109
  • [44] Efficacy and Safety of Oxaliplatin-based Regimens as First-line Chemotherapy in Elderly Patients With Metastatic Colorectal Cancer
    Yamamoto, Seiji
    Fujii, Hironori
    Murayama, Kotaro
    Iihara, Hirotoshi
    Watanabe, Daichi
    Yamada, Yunami
    Kobayashi, Ryo
    Kiyama, Shigeru
    Makiyama, Akitaka
    Urano, Kimihiko
    Matsuhashi, Nobuhisa
    Matsuura, Katsuhiko
    Suzuki, Akio
    ANTICANCER RESEARCH, 2023, 43 (11) : 5099 - 5105
  • [45] Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-III NO16966 trial
    Okines, A.
    Del Puerto, O.
    Cunningham, D.
    Chau, I.
    Van Cutsem, E.
    Saltz, L.
    Cassidy, J.
    BRITISH JOURNAL OF CANCER, 2009, 101 (07) : 1033 - 1038
  • [46] Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-III NO16966 trial
    A Okines
    O del Puerto
    D Cunningham
    I Chau
    E Van Cutsem
    L Saltz
    J Cassidy
    British Journal of Cancer, 2009, 101 : 1033 - 1038
  • [47] FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer
    Loupakis, F.
    Cremolini, C.
    Salvatore, L.
    Masi, G.
    Sensi, E.
    Schirripa, M.
    Michelucci, A.
    Pfanner, E.
    Brunetti, I.
    Lupi, C.
    Antoniotti, C.
    Bergamo, F.
    Lonardi, S.
    Zagonel, V.
    Simi, P.
    Fontanini, G.
    Falcone, A.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 (01) : 57 - 63
  • [48] Bevacizumab plus XELOX as first-line treatment of metastatic colorectal cancer: The OBELIX study
    Antonuzzo, Lorenzo
    Giommoni, Elisa
    Pastorelli, Davide
    Latiano, Tiziana
    Pavese, Ida
    Azzarello, Domenico
    Aieta, Michele
    Pastina, Ilaria
    Di Fabio, Francesca
    Bertolini, Alessandro
    Corsi, Domenico Cristiano
    Mogavero, Selene
    Angelini, Valentina
    Pazzagli, Mario
    Di Costanzo, Francesco
    WORLD JOURNAL OF GASTROENTEROLOGY, 2015, 21 (23) : 7281 - 7288
  • [49] Bevacizumab plus XELOX as first-line treatment of metastatic colorectal cancer:The OBELIX study
    Lorenzo Antonuzzo
    Elisa Giommoni
    Davide Pastorelli
    Tiziana Latiano
    Ida Pavese
    Domenico Azzarello
    Michele Aieta
    Ilaria Pastina
    Francesca Di Fabio
    Alessandro Bertolini
    Domenico Cristiano Corsi
    Selene Mogavero
    Valentina Angelini
    Mario Pazzagli
    Francesco Di Costanzo
    World Journal of Gastroenterology, 2015, (23) : 7281 - 7288
  • [50] FOLFIRI® and Bevacizumab in first-line treatment for colorectal cancer patients: Safety, efficacy and genetic polymorphisms
    Bécouarn Y.
    Cany L.
    Pulido M.
    Beyssac R.
    Texereau P.
    Le Morvan V.
    Béchade D.
    Brunet R.
    Aitouferoukh S.
    Lalet C.
    Mathoulin-Pélissier S.
    Fonck M.
    Robert J.
    BMC Research Notes, 7 (1)
12345